• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    DURECT Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    3/26/25 4:16:15 PM ET
    $DRRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DRRX alert in real time by email
    8-K
    0001082038false00010820382025-03-262025-03-26

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Form 8-K

    Current Report

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    March 26, 2025

    Date of Report

    (Date of earliest event reported)

    DURECT CORPORATION

    (Exact name of Registrant as specified in its charter)

    Delaware

     

    000-31615

     

    94-3297098

    (State or other jurisdiction of

    incorporation or organization)

     

    (Commission

    File Number)

     

    (I.R.S. Employer

    Identification No.)

    10240 Bubb Road

    Cupertino, CA 95014

    (Address of principal executive offices) (Zip code)

    (408) 777-1417

    (Registrant’s telephone number, including area code)

    (Former name or former address, if changed since last report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

     

     

    Title of Each Class

    Trading Symbol

    Name of Each Exchange on Which Registered

    Common Stock $0.0001 par value per share
     

    DRRX

    The NASDAQ Stock Market LLC
    (The Nasdaq Capital Market)

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

     

     


     

    Item 2.02. Results of Operations and Financial Condition.

    On March 26, 2025, DURECT Corporation, a Delaware corporation (“DURECT”), announced its fourth quarter and year ended December 31, 2024 financial results. This Current Report is filed to disclose nonpublic information required to be disclosed by Regulation FD. A copy of DURECT’s press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.

    The information concerning financial results in this Form 8-K and in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information concerning financial results in this Form 8-K and in Exhibit 99.1 shall not be incorporated into any registration statement or other document filed with the Securities and Exchange Commission by the company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

     

    Item 9.01 Financial Statements and Exhibits

    (d) Exhibits

     

    99.1

    Press Release of DURECT Corporation dated March 26, 2025

     

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


     

     

     

    2


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    DURECT Corporation

     

     

     

     

     

    Date: March 26, 2025

     

    By:

     

    /s/ James E. Brown

     

     

     

     

        James E. Brown

        Chief Executive Officer

     

     

     

     

     

     

    3


    Get the next $DRRX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DRRX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DRRX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

      3/26/25 4:05:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

      CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

      3/19/25 4:30:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

      CUPERTINO, Calif., Feb. 4, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that James E. Brown, President and Chief Executive Officer, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, to be held virtually, February 11-12, 2025. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer." alt="DURECT Corporation (www.durect.com) is a late-stage biopharmaceutical company pion

      2/4/25 7:30:00 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by DURECT Corporation

      SC 13G/A - DURECT CORP (0001082038) (Subject)

      11/19/24 5:10:25 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by DURECT Corporation

      SC 13G - DURECT CORP (0001082038) (Subject)

      3/27/24 3:15:14 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by DURECT Corporation

      SC 13G - DURECT CORP (0001082038) (Subject)

      2/16/24 4:09:22 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Financials

    Live finance-specific insights

    See more
    • DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Larsucosterol Phase 2b AHFIRM trial results published in NEJM Evidence in January 2025 Additional AHFIRM data presented in November 2024 at The Liver Meeting 2024 that informed the design of planned Phase 3 trial in alcohol-associated hepatitis (AH) Webcast of earnings call today, March 26 at 4:30 p.m. ET CUPERTINO, Calif., March 26, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the fourth quarter and full year ended December 31, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that t

      3/26/25 4:05:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

      CUPERTINO, Calif., March 19, 2025 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury, today announced that the company will report its fourth quarter and full year 2024 financial results on Wednesday, March 26, 2025. Management will also host a conference call and webcast with investors to discuss the results and provide a business update at 4:30 pm Eastern Time. Details for the call are as follows:

      3/19/25 4:30:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

      -     Seeking to initiate Phase 3 registrational trial for larsucosterol with topline results expected within two years of initiation -     Webcast of Earnings Call Today, November 13 at 4:30 p.m. ET CUPERTINO, Calif., Nov. 13, 2024 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced financial results for the three months ended September 30, 2024 and provided a business update. www.durect.com) is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated DNA methylation to transform the treatment of serious and life-threatening conditions, including acute o

      11/13/24 4:01:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for POSIMIR

      Submission status for DURECT CORP's drug POSIMIR (ORIG-1) with active ingredient BUPIVACAINE has changed to 'Approval' on 02/01/2021. Application Category: NDA, Application Number: 204803, Application Classification: Type 3 - New Dosage Form

      2/2/21 7:24:30 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Medical Officer Sussman Norman

      4 - DURECT CORP (0001082038) (Issuer)

      10/16/24 4:47:15 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Papp Timothy M.

      4 - DURECT CORP (0001082038) (Issuer)

      10/16/24 4:46:24 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President & CEO Brown James E

      4 - DURECT CORP (0001082038) (Issuer)

      10/16/24 4:42:29 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    SEC Filings

    See more
    • SEC Form 10-K filed by DURECT Corporation

      10-K - DURECT CORP (0001082038) (Filer)

      3/27/25 5:26:22 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - DURECT CORP (0001082038) (Filer)

      3/26/25 4:16:15 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by DURECT Corporation

      SCHEDULE 13G/A - DURECT CORP (0001082038) (Subject)

      2/21/25 5:37:08 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Durect with a new price target

      HC Wainwright & Co. reiterated coverage of Durect with a rating of Buy and set a new price target of $6.00

      5/5/21 6:31:29 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chardan Capital reiterated coverage on Durect with a new price target

      Chardan Capital reiterated coverage of Durect with a rating of Buy and set a new price target of $8.00 from $7.00 previously

      2/3/21 8:15:53 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DRRX
    Leadership Updates

    Live Leadership Updates

    See more
    • KaliVir Immunotherapeutics Appoints Schond Greenway as Chief Financial Officer

      KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-mechanistic oncolytic viral immunotherapy programs, today announces the appointment of Schond Greenway as Chief Financial Officer (CFO). With more than 25 years of experience in corporate finance and investment analysis, Mr. Greenway has extensive biotechnology expertise, notably in navigating capital markets and spearheading successful fundraising initiatives. "We are thrilled to welcome Schond as our inaugural CFO. As we advance into clinical development with our lead program VET3-TGI, his proven track record in biotech finance and strategic leadership will be pivotal in steering KaliVir through our next

      9/4/24 8:00:00 AM ET
      $AVTX
      $DRRX
      $HALO
      $MESO
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medicinal Chemicals and Botanical Products
    • DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

      CUPERTINO, Calif., March 21, 2023 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023.  Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires.    "We thank Dave for his many years of service on the DURECT Board and wish him well," stated James E. Brown, D.V.M., President and CEO of DURECT.  "Gail is a seasoned biopharmaceutical executive and we have benefitted from her innovative and strategic thinking as a board member since January

      3/21/23 4:30:00 PM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer

      CUPERTINO, Calif., July 5, 2022 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX), a biopharmaceutical company focused on epigenetic regulation to develop treatments for acute organ injury and chronic liver diseases, today announced the appointment of Timothy M. Papp as its Chief Financial Officer. In this new role, Mr. Papp will direct and oversee all financial and capital markets activities including accounting, financial reporting, financial planning and analysis, financial strategy, and investor relations. "We are excited to welcome Tim to our executive leadership team, as he brings his deep understanding of corporate finance and corporate value drivers to DURECT," stated James E. Brown,

      7/5/22 8:30:00 AM ET
      $DRRX
      Biotechnology: Pharmaceutical Preparations
      Health Care